A high-throughput combinatorial approach for the discovery of a Cremophor EL-free paclitaxel formulation

Pharmaceutical Research

Volumn 20, Issue 8, 2003, Pages 1302-1308

  Chen, Hongming ^a   Zhang, Zhong ^a   McNulty, Chris ^a   Olbert, Cameron ^a   Yoon, Hye Jeong ^b   Lee, Jang Won ^b   Kim, Sung Chul ^b   Seo, Min Hyo ^b   Oh, Hun Seung ^b   Lemmo, Anthony V ^a   Ellis, Stephen J ^a   Heimlich, Ken ^a  

^a TransForm Pharmaceuticals Inc   (United States)

^b Samyang Corporation   (South Korea)

Author keywords

Combinatorial; Cremophor EL free; Formulation; High throughput; Paclitaxel

Indexed keywords

CREMOPHOR; DEOXYCHOLIC ACID; DOCUSATE SODIUM; EXCIPIENT; GAMMA CYCLODEXTRIN; GLYCEROL; MACROGOL; MACROGOL 400; PACLITAXEL; POLOXAMER; POLYSORBATE 20; POLYSORBATE 80;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CHEMICAL COMPOSITION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG ELIMINATION; DRUG FORMULATION; DRUG SOLUBILITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; EXCIPIENTS; GLYCEROL; MALE; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 12444256027     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025021603288     Document Type: Article

References (20)

1. M. C. Wani, H. L. Taylor, and M. E. Wall. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent form Taxus brevifolia. J. Am. Chem. Soc. 93:2325-2327 (1971).
2. A. K. Singla, A. Garg, and D. Aggarwal. Paclitaxel and its formulations. Int. J. Pharm. 235:179-192 (2002).
3. J. D. Adams, K. P. Flora, B. R. Goldspiel, J. W. Wilson, S. G. Arbuck, and R. Finley. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J. Natl. Cancer Inst. Monogr. 15:141-147 (1993).
4. P. P. Constantinides, K. J. Lambert, A. K. Tustian, B. Schneider, S. Lalji, W. Ma, B. Wentzel, D. Kessler, D. Worah, and S. C. Quay. Formulation development and antitumor activity of a filter sterilizable emulsion of paclitaxel. Pharm. Res. 17:175-182 (2000).
5. R. M. Straubinger, A. S. Sharma, M. Murray, and E. Mayhew. Novel Taxol formulations: Taxol-containing liposomes. J. Natl. Cancer Inst. Monogr. 15:69-78 (1993).
6. P. Simamora, R. Dannenfelser, S. E. Tabibi, and S. H. Yalkowsky. Emulsion formulations for intravenous administration of paclitaxel. PDA J. Pharm. Sci. Tech. 52:170-172 (1998).
7. U. S. Sharma, S. V. Balasubramanian, and R. M. Straubinger. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J. Pharm. Sci. 84:1223-1230 (1995).
8. A. J. Bailer. Testing for the equality of area under the curves when using destructive measurement techniques. J. Pharmacokinet. Biopharm. 16:303-309 (1988).
9. L. van Zuylen, J. Verweij, and A. Sparreboom. Role of formulation vehicles in Taxane pharmacology. Invest. New Drugs 19:125-141 (2001).
10. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37:1590-1598 (2001).
11. A. Sparreboom, O. van Tellingen, W. J. Nooijen, and J. H. Beijnen. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9:1-17 (1998).
12. A. Sparreboom, O. van Tellingen, W. J, Nooijen, and J. H. Beijnen, Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 56:2112-2115 (1996).
13. O. van Tellingen, M. T. Huizing, V. R. Nannan Panday, J. H. M. Schellens, W. J. Nooijen, and J. H. Beijnen. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br. J. Cancer 81:330-335 (1999).
14. A. Sparreboom, L. van Zuylen, E. Brouwer, W. J. Loos, P. de Bruijin, H. Gelderblom, M. Pillay, K. Nooter, G. Stoter, and J. Verweij. Cremophor EL- mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 59:1454-1457 (1999).
15. L. van Zuylen, M. O. Karlsson, J. Verweij, E. Brouwer, P. de Bruijin, K. Nooter, G. Stoter, and A. Sparreboom. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother. Pharmacol. 47:309-318 (2001).
16. D. S. Sonnichsen and M. V. Relling. Clinical Pharmacokinetics of paclitaxel. Clin. Pharmacokinet. 27:256-269 (1994).
17. J. H. Beijnen, M. T. Huizing, W. W. ten Bokkel Huinink, C. H. N., Veenhof, J. B. Vermorken, G. Giaccone, and H. M. Pinedo. Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). Semin Oncol. 21:53-62 (1994).
18. U. Vaishampayan, M. D. Ralph, E. Parchment, B. R. Jasti, and M. Hussain. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54:22-29 (1999).
19. S. Nema, R. J. Washkuhn, and R. J. Brendel. Excipients and their use in injectable products. PDA J. Pharm. Sci. Tech 51:166-171 (1997).
20. O. van Tellingen, J. H. Beijnen, J. Verweij, E. J. Scherrenburg, W. J. Nooijen, and A. Sparreboom. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin. Cancer Res. 5:2918-2924 (1999).